A Patient and Investigator-blinded, Randomized, Placebo Controlled Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs LLG 783 (Primary)
- Indications Intermittent claudication; Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Acronyms PAD PoC
- Sponsors Novartis Pharmaceuticals
- 08 Jan 2019 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2018 Planned primary completion date changed from 31 Oct 2018 to 12 Sep 2018.